Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
No 8-K events recorded for this window.
Revvity reported Q1 adjusted EPS of $1.06 with 3% organic growth, while announcing the strategic divestiture of the China immunodiagnostics business. Pro forma excluding China IDx, organic growth was 6%, and life sciences instruments grew mid-single digits for the strongest quarter since early 2023. Academic and government customers returned to growth with US positive for the first time since Q2 2023. EPS guidance was recast to $5.20-$5.30 pro forma, reflecting the divestiture removal.
Revenue Growth | Demand | Regulation Policy | Margin | Guidance Reliability | Cloud & AI | Trade Tariffs | Competitive Dynamics | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 10 | 9 | 3 | 3 | 4 | 1 | 1 | |
| 2025Q1 | 7 | 1 | 3 | 3 | 1 | 3 | 7 | 2 |
| 2025Q2 | 8 | 4 | 7 | 5 | 2 | 1 | 2 | 2 |
| 2025Q3 | 8 | 8 | 5 | 4 | 4 | 2 | 1 | 1 |
| 2025Q4 | 7 | 7 | 2 | 3 | 3 | 3 | 1 | 3 |
| 2026Q1 | 4 | 2 | 1 | 3 | 5 | 4 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10 | 7 | 8 | 8 | 7 | 4 |
| Demand | 9 | 1 | 4 | 8 | 7 | 2 |
| Regulation Policy | 3 | 3 | 7 | 5 | 2 | 1 |
| Margin | 3 | 3 | 5 | 4 | 3 | 3 |
| Guidance Reliability | 4 | 1 | 2 | 4 | 3 | 5 |
| Cloud & AI | 1 | 3 | 1 | 2 | 3 | 4 |
| Trade Tariffs | 7 | 2 | 1 | 1 | ||
| Competitive Dynamics | 1 | 2 | 2 | 1 | 3 |
Calendar quarter Q1 2026Earnings call May 5, 2026
FY2026 Q1 in brief
Revvity reported Q1 adjusted EPS of $1.06 with 3% organic growth, while announcing the strategic divestiture of the China immunodiagnostics business.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +6.97% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Revvity (RVTY), FY2026 Q1: 5/10. Scores: Revvity’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: RVTY daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $729M | +4.8% | $0.78 | -6.3% | 49.3% | 18.1% | 13.0% | $150M |
| FY2025 Q1 | $665M | +2.3% | $0.34 | +53.6% | 56.5% | 10.9% | 6.4% | $112M |
| FY2025 Q2 | $720M | +4.1% | $0.47 | -26.6% | 54.5% | 12.6% | 7.7% | $115M |
| FY2025 Q3 | $699M | +2.2% | $0.40 | -47.6% | 53.6% | 11.7% | 6.7% | $120M |
| FY2025 Q4 | $772M | +5.9% | $0.87 | +11.5% | 43.8% | 14.5% | 12.7% | $163M |
| FY2026 Q1Selected | $711M | +7.0% | $0.36 | +4.5% | 54.5% | 10.7% | 5.7% | $95M |
| FY2026 Q2 | $730M | +1.3% | $0.47 | 0.0% | 57.1% | 12.2% | 7.1% | $184M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
What RVTY and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“We also had a 75 basis point incremental contribution from ACD/Labs, our recent software acquisition.”
Revvity's recent acquisition of ACD/Labs contributed roughly 75 basis points of inorganic revenue growth in the quarter.
“We announced the Lilly TuneLab partnership, which is a great launch path for Xynthetica, leveraging the ecosystem that Lilly brings to the table.”
Revvity partnered with Lilly on TuneLab as a launch channel for its Xynthetica AI software platform, leveraging Lilly's ecosystem.
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Vijay Kumar | Evercore ISI | 13 questions · 15% challenging |
| Dan Brennan | TD Cowen | 11 questions · 9% challenging |
| Patrick Donnelly | Citigroup | 10 questions · 0% challenging |
| Mike Ryskin | Bank of America | 9 questions · 22% challenging |
| Puneet Souda | Leerink Partners | 9 questions · 11% challenging |
| Luke Sergott | Barclays | 9 questions · 0% challenging |
“The well-known research from Gartner recently published a research paper highlighting our internal AI deployment, which stands out across the industries that they've researched.”
Revvity cites Gartner research that highlighted Revvity's internal AI deployment as standing out across industries, using Gartner as an outside validator.
“a better-than-expected contribution from our Genomics England contract.”
Revvity's reproductive health business benefited from stronger-than-expected sample volumes under its Genomics England newborn-screening contract.
| RBC Capital Markets |
| 8 questions · 0% challenging |
| Tycho Peterson | Jefferies | 8 questions · 13% challenging |
| Dan Arias | Stifel | 8 questions · 0% challenging |
| Catherine Schulte | Robert W. Baird | 8 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Evercore ISI | 1 analyst | 13 questions · 15% challenging |
| TD Cowen | 1 analyst | 11 questions · 9% challenging |
| Citigroup | 1 analyst | 10 questions · 0% challenging |
| Leerink Partners | 1 analyst | 9 questions · 11% challenging |
| Barclays | 1 analyst | 9 questions · 0% challenging |
| Bank of America | 1 analyst | 9 questions · 22% challenging |
| Stifel | 1 analyst | 8 questions · 0% challenging |
| Jefferies | 1 analyst | 8 questions · 13% challenging |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
RVTY Revvity | 5 | +7.0% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| ILMN Illumina, Inc. | 8 | +4.8% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |